Localization of pancreatic cancer with radiolabeled monoclonal antibody PAM4

Critical Reviews in Oncology/Hematology

Volumn 39, Issue 1-2, 2001, Pages 147-154

  Gold, David V ^a   Cardillo, Thomas ^a   Goldenberg, David M ^a   Sharkey, Robert M ^a  

^a GARDEN STATE CANCER CENTER   (United States)

Author keywords

Antibody; PAM4; Pancreatic cancer; Radioimmunodetection

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; IMMUNOGLOBULIN G; INDIUM 111; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PAM4; TECHNETIUM 99M; UNCLASSIFIED DRUG; YTTRIUM 90;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; BONE MARROW TOXICITY; CANCER GRAFT; CANCER LOCALIZATION; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DOSIMETRY; DRUG TARGETING; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IMAGING; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PANCREAS CANCER; TISSUE DISTRIBUTION;

AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CA-15-3 ANTIGEN; FEMALE; HUMANS; MALE; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; PHARMACOKINETICS; RADIOIMMUNODETECTION; RADIOIMMUNOTHERAPY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034975884     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(01)00114-7     Document Type: Conference Paper

References (43)

1. Cancer Statistics, 1999
2. Cancer of the pancreas
3. Carcinoma of the body and tail of the pancreas: is curative resection justified?
4. Surgical treatment of pancreatic cancer: the United States experience
5. Assessing clinical benefit in the treament of pancreas cancer: gemcitabine compared to 5-fluorouracil
6. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial
7. Current status of and future prospects for the medical management of adenocarcinoma of the exocrine pancreas
8. Treatment of cancer of the pancreas by precision high dose external photon beam and intraoperative electron beam therapy
9. Intraoperative radiation therapy adjuvant to resection of pancreatic cancer
10. Intaoperative radiation therapy for pancreatic carcinoma
11. Prospects of radioimmunotherapy in epithelial ovarian cancer: Results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies
12. Radioimmunotherapy of small volume disease of colorectal cancer metastatic to liver: Preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study
13. Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin
14. Targeting of xenografted pancreatic cancer with a new monoclonal antibody, PAM4
15. Initial studies of Mab-PAM4 targeting to xenografted orthotopic pancreatic cancer
16. Initial targeting, biodistribution and pharmacokinetic screening of the monoclonal antibody PAM4 for immunoscintigraphy in patients with pancreatic cancer
17. Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2
18. 90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies
19. Preclinical evaluation of an 'instant' 99mTc-labeling kit for antibody imaging
20. Comparison of therapeutic efficacy and host toxicity of two different I-131 labeled antibodies and their fragments in the GW-39 colonic cancer xenograft model
21. Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies
22. Phase II study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer
23. Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer
24. Imaging and therapy of gastrointestinal cancers with radiolabeled antibodies
25. Enhancement of tumor uptake by stabilized Fab′ homo-oligomers of a chimeric monoclonal antibody against carcinoembryonic antigen
26. Therapy and imaging of pancreatic carcinoma xenografts with radioiodine-labeled chimeric monoclonal antibody A10 and its Fab fragment
27. Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: Influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics
28. Radioimmunodetection with 111In-labeled monoclonal antibody Nd2 in patients with pancreatic cancer
29. Preoperative clinical radioimmunodetection of pancreatic cancer by 111 In-labeled chimeric monoclonal antibody Nd2
30. Assessment of disseminated pancreatic cancer: a comparison of traditional exploratory laparotomy and radioimmunoguided surgery
31. Single-chain antibodies in pancreatic cancer
32. Biodistribution of murine and chimeric Fab fragments of the monoclonal antibody A7 in human pancreatic cancer
33. Generation and application of monoclonal antibody to human pancreatic carcinoma
34. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer
35. The usefulness of serial changes in serum CA19-9 levels in the diagnosis of pancreatic cancer
36. Comparative study of carbohydrate antigen 195 and carcinoembryonic antigen for the diagnosis of pancreatic carcinoma
37. Prognostic significance of preimmunotherapy serum CA27.29 (MUC-1) mucin level after active specific immunotherapy of metastatic adenocarcinoma patients
38. Expression of mucin antigens in human cancers and its relationship with malignancy potential
39. Pancreatic tumour marker anti-mucin antibody CAM 17.1 reacts with a sialyl blood group antigen, probably I, which is expressed throughout the human gastrointestinal tract
40. Radioimmunotherapy for pancreatic carcinoma using (131)I-labeled monoclonal antibody Nd2 in xenografted nude mice
41. Therapy and imaging of pancreatic carcinoma xenografts with radioiodine-labeled chimeric monoclonal antibody A10 and its Fab fragment
42. Comparative dual label study of first and second generation anti-tumor-associated glycoprotein-72 monoclonal antibodies in colorectal cancer patients
43. Radioimmunodetection of colorectal cancer metastases with 131I-labeled monoclonal antibody B72.3: a pilot study to determine efficacy of detection and pharmacokinetics